Cargando…

Comparative efficacy of escitalopram in the treatment of major depressive disorder

BACKGROUND: Escitalopram is an allosteric selective serotonin reuptake inhibitor (SSRI) with some indication of superior efficacy in the treatment of major depressive disorder. In this systematic review, we critically evaluate the evidence for comparative efficacy and tolerability of escitalopram, f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Mazen K, Lam, Raymond W
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056172/ https://www.ncbi.nlm.nih.gov/pubmed/21430793 http://dx.doi.org/10.2147/NDT.S12531

Ejemplares similares

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials
por: Li, Guanjun, et al.
Publicado: (2017)

Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder
por: Nam, Beomwoo, et al.
Publicado: (2017)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
por: Alkahtani, Manal E., et al.
Publicado: (2021)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
por: Martens, Marieke A. G., et al.
Publicado: (2021)

Mild cognitive disorder and depression: treatment with combination of galantamine and escitalopram
por: Zarra, Julio, et al.
Publicado: (2010)

Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
por: Kadam, Renuka L., et al.
Publicado: (2020)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study
por: Urade, Chetan S., et al.
Publicado: (2015)

Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication
por: Muhonen, Leea H, et al.
Publicado: (2008)

Efficacy of escitalopram oxalate for patients with post-stroke depression
por: Xu, Ji-hua, et al.
Publicado: (2018)

Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial
por: Gupta, Brij Mohan, et al.
Publicado: (2016)

Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report
por: Arshad, Hareem, et al.
Publicado: (2022)

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
por: Jiang, Kaida, et al.
Publicado: (2017)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder
por: Kamishikiryo, Toshiharu, et al.
Publicado: (2022)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder
por: Adjei, Kwame, et al.
Publicado: (2023)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
por: Raj, Rajnish, et al.
Publicado: (2021)

Efficacy and safety of generic escitalopram versus Lexapro in the treatment of major depression: a multicenter double-blinded randomized controlled trial
por: Yu, Yimin, et al.
Publicado: (2013)

Reversible Hemifacial Spasm after Starting Escitalopram
por: Basheikh, Mazen Abdulrahaman
Publicado: (2020)

Comparing the Therapeutic Effects of Crocin, Escitalopram and Co-Administration of Escitalopram and Crocin on Learning and Memory in Rats with Stress-Induced Depression
por: Joodaki, Mehran, et al.
Publicado: (2021)

Efficacy and tolerability of Escitalopram in patients with chronic kidney disease undergoing hemodialysis having depressive disorder
por: Naik1, Bhavyashree Laxman, et al.
Publicado: (2022)

Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2019)

Spatio-temporal dynamics of EEG features during sleep in major depressive disorder after treatment with escitalopram: a pilot study
por: Wu, Li, et al.
Publicado: (2020)

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder
por: Zhang, Shudong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6c94pqdsp00q688nqh5tc1t8dd